Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Enanta Pharmaceuticals (ENTA) EBT Margin (2016 - 2025)

Enanta Pharmaceuticals' EBT Margin history spans 14 years, with the latest figure at 64.0% for Q4 2025.

  • For Q4 2025, EBT Margin rose 6989.0% year-over-year to 64.0%; the TTM value through Dec 2025 reached 108.62%, up 5125.0%, while the annual FY2025 figure was 127.9%, 4625.0% up from the prior year.
  • EBT Margin reached 64.0% in Q4 2025 per ENTA's latest filing, up from 123.42% in the prior quarter.
  • In the past five years, EBT Margin ranged from a high of 64.0% in Q4 2025 to a low of 211.37% in Q1 2023.
  • Average EBT Margin over 5 years is 149.11%, with a median of 149.66% recorded in 2021.
  • Peak YoY movement for EBT Margin: plummeted -10888bps in 2021, then surged 7638bps in 2025.
  • A 5-year view of EBT Margin shows it stood at 109.05% in 2021, then decreased by -13bps to 123.04% in 2022, then tumbled by -54bps to 189.02% in 2023, then grew by 29bps to 133.89% in 2024, then skyrocketed by 52bps to 64.0% in 2025.
  • Per Business Quant, the three most recent readings for ENTA's EBT Margin are 64.0% (Q4 2025), 123.42% (Q3 2025), and 99.52% (Q2 2025).